K. Boye

European standard clinical practice recommendations for children and adolescents with Primary and Recurrent osteosarcoma

S. Bielack, M. A. van de Sande, L. Kager, 2023, EJC Paediatric Oncology.

A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?

A. Marchais, L. Kager, M. Le Deley, 2023, Cancer treatment reviews.

Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors

A. Czarnecka, M. Spałek, A. Szumera-Ciećkiewicz, 2023, Cancers.

Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets

R. Lothe, O. Lingjærde, B. Bjerkehagen, 2023, EBioMedicine.

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

M. von Mehren, H. Gelderblom, P. Schöffski, 2024, Nature medicine.

Biological Sample Collection to Advance Research and Treatment: A Fight Osteosarcoma Through European Research and Euro Ewing Consortium Statement

U. Dirksen, M. Toulmonde, A. Marchais, 2024, Clinical cancer research : an official journal of the American Association for Cancer Research.

Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma

M. Hentze, O. Myklebost, L. Meza-Zepeda, 2024, Nature communications.

Discontinuation of imatinib in patients with oligometastatic gastrointestinal stromal tumour who are in complete radiological remission: a prospective multicentre phase II study

H. Joensuu, B. Røsok, Anne Marit Wiedswang, 2024, Acta oncologica.